Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization: Cyclerion Therapeutics (CYCN)

Corporate emblem and logo of Cyclerion Therapeutics Inc. (CYCN)

The asset value for Cyclerion Therapeutics (CYCN), reaching 0.00 as tracked on the chart, is based on the development of drugs for dementia and cognitive impairment via sGC activation. Small molecule patents and strict regulatory oversight create significant barriers to entry for low-cost generics. Meanwhile, a strategic scientific pivot toward a narrow CNS segment protects the company from aggressive price wars with competitors.

Cyclerion Therapeutics Inc. - CYCN Company Value to EBITDA (period 11/23/2025 - 09/09/2026)

Analytical breakdowns for Cyclerion Therapeutics

- current price and projected stock value:
- company stock exchange capitalization indicators:
Initial company analysis:CYCN (Cyclerion Therapeutics Inc.)
Product sample of Cyclerion Therapeutics, Inc.

A conservative approach to analyzing Cyclerion Therapeutics (CYCN) requires strict control of the debt load relative to operating profit. This metric compares the total enterprise value, including net debt, to EBITDA, determining the payback period for assets based on current cash flow. By analyzing the EV/EBITDA ratio on the valuation chart, an investor can assess the company's resilience to medical patent impairment risks and the effectiveness of its intellectual property restructuring.

Competitor analysis for Cyclerion Therapeutics

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Inc BIIB|EV/EBITDA Multiple neurocrine.com NBIX|RGC - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Axsome|ACAD: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation XENE|VKTX (Viking Therapeutics Corp) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation SUPN (Supernus)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Catalyst Pharma (CPRX)|DNLI (Denali Therapeutics Inc) - Business Value to Operating Income Before Depreciation|Harmony Pharma - Enterprise Value to EBITDA Ratio|BHVN: Enterprise Value to Operating Income Before Depreciation|Amylyx Pharmaceuticals - EV/EBITDA Multiple|Company Value to EBITDA trevitherapeutics.com|PRAX: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio AVXL (Anavex Life Sciences Corp.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CeriBell, Inc.|Company Value to EBITDA Prothena Biosciences PRTA|Enterprise Value to EBITDA Ratio ALEC (Alector Therapeutics)|Total Company Value to Operating Income Before Depreciation Ratio Annexon, Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Omeros Corporation OMER|NGNE - Enterprise Value to EBITDA Ratio|ACIU - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio VYGR|NMRA: EV/EBITDA Multiple|Scilex Holding Company - Business Value to Operating Income Before Depreciation|TVGN (Tevogen Bio Holdings, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Alpha Cognition|EV/EBITDA Multiple CGTX|IKT - Company Value to EBITDA|EV/EBITDA Multiple SAVA (cassavasciences.com)|Business Value to Operating Income Before Depreciation ASRT|Coya Therapeutics Inc - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio vistagen.com VTGN|Ovid Therapeutics Inc. (OVID) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Acumen Pharmaceuticals, Inc (ABOS) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CervoMed Inc.|Alterity Therapeutics (ATHE) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CLNN|PEPG - Company Value to EBITDA|EV/EBITDA Multiple JUNS (Jupiter Neurosciences, Inc.)|RLMD - Enterprise Value to EBITDA Ratio|ANVS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Multiple Grace Therapeutics (GRCE)|AIFF: EV/EBITDA Multiple|ANEW Medical, Inc. (KLTO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeuroSense Therapeutics Ltd.|RVPH: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple MTVA|EV/EBITDA Multiple NeurAxis (NRXS)|Helius Medical Technologies, Inc. - Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio Passage Bio, Inc. (PASG)|Neuphoria - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation NERV (Minerva)|ATHA: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation ADXN|Enterprise Value to EBITDA Ratio ALZN|PTIX: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple KTTA|Enterprise Value to Operating Income Before Depreciation Ratio CRGT|Avenue Therapeutics Inc - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BCLI|CARA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation CHRO (Chromocell Therapeutics Corp)|ELYM: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation ITCI|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Longboard Pharmaceuticals Inc|marinuspharma.com (MRNS) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio NKGN (NKGen Biotech, Inc.)|NRBO - Company Value to EBITDA|EV/EBITDA Multiple SAGE (Sage Therapeutics, Inc)|SNPX: Enterprise Value to Operating Income Before Depreciation|Trevena Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio vigilneuro.com VIGL|WENA: EV/EBITDA Multiple|Company Value to EBITDA Cerevel Therapeutics Inc (CERE)